Key result
Doxorubicin treatment resulted in significantly increased tumour volume compared to vehicle control in a murine breast cancer model, indicating drug resistance mediated by the MAPK/ERK pathway.
Why the study?
Doxorubicin can induce drug resistance resulting in poor survival, and the interaction between signaling pathways may promote resistance through proliferation, cell cycle progression, and evasion of apoptosis.
Does doxorubicin induce drug resistance and affect cell death and survival signalling pathways in a murine breast tumour model?
Does doxorubicin induce drug resistance and affect cell death and survival signalling pathways in a murine breast tumour model?
p-value: p=<0.05
In a murine breast cancer model, doxorubicin-induced drug resistance and tumor growth are associated with adaptive activation of the MAPK/ERK pathway.
No takes yet. Share an insight, caveat, or question.
Should not alter doxorubicin use; hypothesis-generating for MAPK/ERK targeting in resistant breast cancer.
Christowitz et al. (2019) studied Breast cancer (n=47). Doxorubicin vs. Vehicle (Hank's Balances Salt Solution) was evaluated on Tumour volume (p=<0.05). Doxorubicin treatment resulted in significantly increased tumour volume compared to vehicle control in a murine breast cancer model, indicating drug resistance mediated by the MAPK/ERK pathway.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: